UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Effect of renal impairment on the pharmacokinetics of exenatide

British journal of clinical pharmacology, 2007-09, Vol.64 (3), p.317-327

2007

Volltextzugriff (PDF)

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Regulatory peptides, 2008-11, Vol.151 (1), p.123-129

2008

Volltextzugriff (PDF)

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

Diabetes therapy, 2020-08, Vol.11 (8), p.1709-1720

2020

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

Endocrine Journal, 2009, Vol.56(8), pp.951-962

2009

Volltextzugriff (PDF)

Lepodisiran for Elevated Lipoprotein(a)-Reply

JAMA : the journal of the American Medical Association, 2024-04, Vol.331 (16), p.1417

2024

Volltextzugriff (PDF)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data

Clinical pharmacokinetics, 2021-11, Vol.60 (11), p.1423-1434

2021

Volltextzugriff (PDF)

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-09, Vol.330 (11), p.1042

2023

Volltextzugriff (PDF)

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

Journal of clinical pharmacology, 2006-10, Vol.46 (10), p.1179-1187

2006

Volltextzugriff (PDF)

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

JAMA : the journal of the American Medical Association, 2023-12, Vol.330 (21), p.2075

2023

Volltextzugriff (PDF)

SOLBINSIRAN, A GALNAC-CONJUGATED SIRNA TARGETING ANGPTL3, REDUCES ATHEROGENIC LIPOPROTEINS IN INDIVIDUALS WITH MIXED DYSLIPIDAEMIA IN A DURABLE AND DOSEDEPENDENT MANNER

Journal of the American College of Cardiology, 2024-04, Vol.83 (13), p.1673-1673

2024

Volltextzugriff (PDF)

Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin

Journal of clinical pharmacology, 2005-09, Vol.45 (9), p.1032-1037

2005

Volltextzugriff (PDF)

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1789-1798

2020

Volltextzugriff (PDF)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial

Clinical pharmacokinetics, 2020-12, Vol.59 (12), p.1589-1599

2020

Volltextzugriff (PDF)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Clinical pharmacokinetics, 2020-12, Vol.59 (12), p.1601-1610

2020

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites

Clinical therapeutics, 2022-06, Vol.44 (6), p.836-847

2022

Volltextzugriff (PDF)

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Diabetes care, 2015-12, Vol.38 (12), p.2226-2233

2015

Volltextzugriff (PDF)

Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus

Diabetes, obesity & metabolism, 2023-07, Vol.25 (7), p.1964-1972

2023

Volltextzugriff (PDF)

1040-P: Ultra-Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) Consistently across Study Populations: A Meta-analysis of Pharmacokinetic and Glucodynamic Data

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

1036-P: Bioequivalence of Ultra-Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

Diabetes, obesity & metabolism, 2017-01, Vol.19 (1), p.33-39

2017

Volltextzugriff (PDF)

1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(55)

Sprache

Englisch
(54)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Humans
(29)
Insulin
(25)
Male
(24)
Pharmacokinetics
(23)
Adult
(22)
Female
(21)
Middle Aged
(21)
Diabetes
(20)
Glucose
(19)
Cross-Over Studies
(17)
Hypoglycemic Agents - Administration & Dosage
(16)
Endocrinology & Metabolism
(15)
Hypoglycemic Agents - Pharmacokinetics
(14)
Pharmacology & Pharmacy
(12)
Double-Blind Method
(11)
Young Adult
(10)
Exenatide
(9)
Glucose Clamp Technique
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of renal impairment on the pharmacokinetics of exenatide

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium

Lepodisiran for Elevated Lipoprotein(a)-Reply

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

SOLBINSIRAN, A GALNAC-CONJUGATED SIRNA TARGETING ANGPTL3, REDUCES ATHEROGENIC LIPOPROTEINS IN INDIVIDUALS WITH MIXED DYSLIPIDAEMIA IN A DURABLE AND DOSEDEPENDENT MANNER

Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus

1040-P: Ultra-Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) Consistently across Study Populations: A Meta-analysis of Pharmacokinetic and Glucodynamic Data

1036-P: Bioequivalence of Ultra-Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

Suchergebnisse filtern